RAF/RAS oncogenes and mismatch-repair status
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Genes of the RAF family encode kinases that are regulated by Ras and mediate cellular responses to growth signals. Activating mutations in one RAF gene, BRAF, have been found in a high proportion of melanomas and in a small fraction of other cancers. Here we show that BRAF mutations in colorectal cancers occur only in tumours that do not carry mutations in a RAS gene known as KRAS, and that BRAF mutation is linked to the proficiency of these tumours in repairing mismatched bases in DNA. Our results not only provide genetic support for the idea that mutations in BRAF and KRAS exert equivalent effects in tumorigenesis, but also emphasize the role of repair processes in establishing the mutation spectra that underpin human cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [160]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Self-citationStabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines
Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., & Polakis, P. (1997) · Science · doi:10.1126/science.275.5307.1790 · Cited by 1,223
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Sparks, A. B., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · PubMed · Cited by 1,008
Self-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456
Mechanisms underlying losses of heterozygosity in human colorectal cancers
Thiagalingam, S., Laken, S., Willson, J. K. V., Markowitz, S. D., Kinzler, K. W., Vogelstein, B., & Lengauer, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051625398 · Cited by 228
Self-citationPrevalence of somatic alterations in the colorectal cancer cell genome
Wang, T.-L., Rago, C., Silliman, N., Ptak, J., Markowitz, S., Willson, J. K. V., Parmigiani, G., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261714699 · Cited by 177
Self-citationOncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors
Storm, S. M., & Rapp, U. R. (1993) · Toxicology Letters · doi:10.1016/0378-4274(93)90056-4 · Cited by 53
Research works printed but not linked: 2
- Sparks, A. B., Morin, P. J., Vogelstein, B. & Kinzler, K. W. Cancer Res. 58, 1130–1134 (1998).
- Markowitz, S. J. Clin. Oncol. 18 (suppl.), 75–80 (2000).
Cited by
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
“BRAF is reportedly mutated in 70% of malignant melanomas (10), in 33% of papillary thyroid carcinomas (11), and in lower frequencies in other cancers (12).”
BackgroundCancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp127 · Cited by 2,890
“Genetic instability in cancer reflects an increased rate of DNA alterations in tumor cells, which may arise either from increased rates of damage or defective mechanisms that maintain genetic integrity within cells [100,101].”
BackgroundMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
“Here of malignant melanomas and occur with moderate towe show that of 22 B-RAF mutants analyzed, 18 have high frequency in colorectal (Rajagopalan et al., 2002),elevated kinase activity and signal to ERK in vivo.”
BackgroundTargeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
“…in melanomas, colorectal carcinomas, papillary thyroid carcinomas, serous ovarian carcinomas and lung cancers suggests that Ras function is facilitated primarily by activation of Raf (Rajagopalan et al., 2002; Mercer and Pritchard, 2003; Singer et al., 2003; Vos et al., 2003; Sieben et al., 2004).”
BackgroundMicrosatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.001 · Cited by 2,284
“In some cells, B-Raf mutations are believed to be initiating events but not sufficient for full-blown neoplastic transformation [122,123].”
BackgroundMolecular Basis of Colorectal Cancer
Markowitz, S. D., & Bertagnolli, M. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804588 · Cited by 2,052
Molecular Genetics of Colorectal Cancer
Fearon, E. R. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130235 · Cited by 1,805
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Self-citationKimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,707
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., Ince, W. L., Jänne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,461
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
“…and other common genetic alterations in thyroid cancer Mutual exclusivity between BRAF mutation and ras mutation was seen in several types of human cancer, including, for example, colorectal cancer (Rajagopalan et al. 2002), melanoma (Omholt et al. 2003), and ovarian cancer (Singer et al. 2003).”
BackgroundShih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
The MAPK signalling pathways and colorectal cancer
Fang, J. Y., & Richardson, B. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70168-6 · Cited by 1,185
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
Serrated Lesions of the Colorectum: Review and Recommendations From an Expert Panel
Rex, D. K., Ahnen, D. J., Baron, J. A., Batts, K. P., Burke, C. A., Burt, R. W., Goldblum, J. R., Guillem, J. G., Kahi, C. J., Kalady, M. F., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.161 · Cited by 1,117
Targeting the mitogen-activated protein kinase cascade to treat cancer
Sebolt-Leopold, J. S., & Herrera, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1503 · Cited by 1,108
Microsatellite Instability in Colorectal Cancer-the Stable Evidence
Vilar, E., & Gruber, S. B. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.237 · Cited by 1,063
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030838 · Cited by 1,042
“Nucleotide 1796, the only mutational site in thyroid carcinomas, was the most frequently affected hot spot in other types of human cancers where BRAF is mutated, such as malignant melanoma and colorectal carcinoma (11, 12).”
BackgroundRole of the Serrated Pathway in Colorectal Cancer Pathogenesis
Leggett, B., & Whitehall, V. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.066 · Cited by 977
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Self-citationBRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 922
“This observation is also consistent with the reported inverse association between the presence of BRAF and RAS mutations in other cancer types (4, 7 ,8).”
ResultMutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915
“The high frequency of mutations in these hotspots is reminiscent of mutations found in oncogenes such as KRAS and BRAF (Bos et al., 1987; Davies et al., 2002; Rajagopalan et al., 2002), and is consistent with the premise that alterations in PIK3CA are activating.”
BackgroundSelf-citationGlucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
Yun, J., Rago, C., Cheong, I., Pagliarini, R., Angenendt, P., Rajagopalan, H., Schmidt, K., Willson, J. K. V., Markowitz, S., Zhou, S., et al. (2009) · Science · doi:10.1126/science.1174229 · Cited by 914
Self-citationMutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma
Singer, G., Oldt, R., Cohen, Y., Wang, B. G., Sidransky, D., Kurman, R. J., & Shih, I.-M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.484 · Cited by 854
“BRAF at codon 599 and KRAS mutations at codons 12 and 13 in ovarian carcinoma is consistent with a similar finding in melanoma and colorectal carcinoma and lends strong support for the view that BRAF and KRAS mutations have equivalent effects on tumorigenesis (2, 5 ).”
BackgroundResultVemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
Garnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 799
Wnt/β-catenin signaling in cancer stemness and malignant behavior
Fodde, R., & Brabletz, T. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.007 · Cited by 785
Venderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., Kaplan, R., Quirke, P., Seymour, M. T., Richman, S. D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0332 · Cited by 772
“The strong inter-relationship between BRAF and dMMR is well established in early-stage colorectal cancer (14, 34); however, the etiology of both alterations still needs to be”
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746
Self-citationLinardou, H., Dahabreh, I. J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., Papadimitriou, C. A., & Murray, S. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70206-7 · Cited by 739
Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers
Samowitz, W. S., Sweeney, C., Herrick, J., Albertsen, H., Levin, T. R., Murtaugh, M. A., Wolff, R. K., & Slattery, M. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0404 · Cited by 737
“BRAF is a part of the Ras/Raf/MEK/MAP signal transduction pathway, and oncogenic mutations in BRAF, nearly all of which are the V600E mutation, have been reported in colon cancer (1, 2).”
BackgroundColorectal carcinoma: Pathologic aspects.
Fleming, M., Ravula, S., Tatishchev, S. F., & Wang, H. L. (2012) · PubMed · doi:10.3978/j.issn.2078-6891.2012.030 · Cited by 713
“First, activating BRAF and KRAS mutations are almost always mutually exclusive (135,136), and thus mutation testing of the BRAF gene should be considered following a negative KRAS mutation analysis.”
BackgroundBRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum
Kambara, T., Simms, L. A., Whitehall, V. L. J., Spring, K. J., Wynter, C. V. A., Walsh, M. D., Barker, M. A., Arnold, S., McGivern, A., Matsubara, N., et al. (2004) · Gut · doi:10.1136/gut.2003.037671 · Cited by 722
“In the study of Rajagopalan et al , an association between MMR and BRAF mutation was reported 26 but sporadic and inherited (HNPCC) cancers were not considered separately.”
BackgroundMethodResultInfluentialGenetic prognostic and predictive markers in colorectal cancer
Walther, A., Johnstone, E., Swanton, C., Midgley, R., Tomlinson, I., & Kerr, D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2645 · Cited by 705
“BRAF acts downstream from KRAS , and mutations in the two genes seem to be mutually exclusiv”
BackgroundPhase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
Soares, P., Trovisco, V., Rocha, A. S., Lima, J., Castro, P., Preto, A., Máximo, V., Botelho, T., Seruca, R., & Sobrinho-Simões, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206706 · Cited by 679
“In all, 5–10% of the colon cancers were shown to have BRAF mutation, but in the setting of the mismatch repair deficient tumors, the frequency rose to 30% of the tumors (Rajagopalan et al., 2002).”
BackgroundResultInfluentialMutual exclusivity analysis identifies oncogenic network modules
Ciriello, G., Cerami, E., Sander, C., & Schultz, N. (2012) · Genome Research · doi:10.1101/gr.125567.111 · Cited by 675
“…signaling pathway) (Sparks et al. 1998), and BRAF and KRAS mutations (both involved in the common RAS/RAF signaling pathway) in colorectal cancer (Rajagopalan et al. 2002); and mutual exclusivity between BRCA1/2 mutations and BRCA1 epigenetic silencing in serous ovarian cancer (The Cancer Genome…”
BackgroundRoles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Abrams, S. L., Lee, J. T., Chang, F., Bertrand, F. E., Navolanic, P. M., Terrian, D. M., Franklin, R. A., D’Assoro, A. B., et al. (2006) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2006.01.004 · Cited by 664
“In some cells, B-Raf mutations are believed to be initiating events and not sufficient for full-blown neoplastic transformation (Rajagopalan et al., 2002; Yuen et al., 2002).”
BackgroundSomatic mutations of epidermal growth factor receptor signaling pathway in lung cancers
Shigematsu, H., & Gazdar, A. F. (2006) · International Journal of Cancer · doi:10.1002/ijc.21496 · Cited by 657
“Of interest, mutations of RET, RAS and BRAF are mutually exclusive in thyroid papillary cancer,(37) as are KRAS and BRAF in colorectal cancers.(38,39) These results indicate that simultaneous mutations of multiple genes in the same signaling pathways are not required for lung cancer pathogenesis as well as for other t…”
BackgroundDeng, N., Goh, L. K., Wang, H., Das, K., Tao, J., Tan, I. B., Zhang, S., Lee, M., Wu, J., Lim, K. H., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301839 · Cited by 645
“19 e 21 Additional details, including methods associated with dimension reduction permutation (DRP), fl uorescence in-situ hybridisation (FISH) assays, and functional assays, are presented in the supplementary materials (available online only).”
MethodPratilas, C. A., Taylor, B. S., Ye, Q., Viale, A., Sander, C., Solit, D. B., & Rosen, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900780106 · Cited by 614
Pathways of Colorectal Carcinogenesis
Nguyen, L. H., Goel, A., & Chung, D. C. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.08.059 · Cited by 606
Genetic and biological hallmarks of colorectal cancer
Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021) · Genes & Development · doi:10.1101/gad.348226.120 · Cited by 573
“With respect to the RAS pathway in CRC, the RAS effector, BRAF, is mutated in 10%–15% (Davies et al. 2002; Rajagopalan et al. 2002; Vaughn et al. 2011) of early-stage CRC and around 5% in stage IV CRC, in the hotspot codon 600 (V600E) (Vaughn et al. 2011), and is mutually exclusive of RAS mutations…”
BackgroundSamowitz, W. S., Albertsen, H., Herrick, J., Levin, T. R., Sweeney, C., Murtaugh, M. A., Wolff, R. K., & Slattery, M. L. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.020 · Cited by 577
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Velculescu, V. E. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1164 · Cited by 538
Self-citationSIGNALING PATHWAYS IN INTESTINAL DEVELOPMENT AND CANCER
Sancho, E., Batlle, E., & Clevers, H. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.092805 · Cited by 532
Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., & Bardelli, A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp280 · Cited by 429
Self-citationMutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers
Wang, Z., Shen, D., Parsons, D. W., Bardelli, A., Sager, J., Szabo, S., Ptak, J., Silliman, N., Peters, B. A., van der Heijden, M. S., et al. (2004) · Science · doi:10.1126/science.1096096 · Cited by 522
Self-citationOncogenic PI3K and its role in cancer
Samuels, Y., & Ericson, K. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000198021.99347.b9 · Cited by 521
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas
Pfister, S., Janzarik, W. G., Remke, M., Ernst, A., Werft, W., Becker, N., Toedt, G., Wittmann, A., Kratz, C., Olbrich, H., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33656 · Cited by 523
Malignant melanoma: genetics and therapeutics in the genomic era
Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 511
“While these biological outcomes indicate distinct roles for NRAS and BRAF activation in melanoma genesis, some functional overlap is suggested by the predominantly nonconcurrent occurrence of activated NRAS and B-RAF alleles in melanoma and other tumor types (Davies et al. 2002; Rajagopalan et al. 2002; Goel et al. 20…”
BackgroundBentires-Alj, M., Paez, J. G., David, F. S., Keilhack, H., Halmos, B., Naoki, K., Maris, J. M., Richardson, A., Bardelli, A., Sugarbaker, D. J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1923 · Cited by 509
“For example, 60% of melanomas have B-RAF mutations (19), and 60% of colorectal cancers have either RAS or B-RAF mutations that occur in a mutually exclusive fashion (20).”
BackgroundSelf-citationO'Brien, M. J., Yang, S., Mack, C., Xu, H., Huang, C. S., Mulcahy, E., Amorosino, M., & Farraye, F. A. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213313.36306.85 · Cited by 509
“Methylation of CpG islands of the promoter regions of suppressor and mutator genes is thought to be the major mechanism of progression to malignancy in these sporadic MSI cancers;(12,20) other distinctive characteristics of this category of colon cancers are a strong association with activating mutations of BRAF and a…”
BackgroundThe serrated pathway to colorectal carcinoma: current concepts and challenges
Bettington, M., Walker, N., Clouston, A., Brown, I., Leggett, B., & Whitehall, V. (2013) · Histopathology · doi:10.1111/his.12055 · Cited by 502
“first described BRAF mutations in CRC in 2002.(36) Importantly, they also found that BRAF and KRAS mutations are mutually exclusive, and that BRAF mutations strongly correlate with both MSI and CIMP.”
BackgroundIdentification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, T. C., Bauer, M., Davies, F. E., Rosenthal, A., Wang, H., Qu, P., Hoering, A., et al. (2018) · Blood · doi:10.1182/blood-2018-03-840132 · Cited by 475
“11-13 We have shown this previously with translocation groups and their partner genes, such as t(11;14) and mutation of CCND1.”
BackgroundInfluentialRegulation of MAPKs by growth factors and receptor tyrosine kinases
Katz, M., Amit, I., & Yarden, Y. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.01.002 · Cited by 467
Adnane, L., Trail, P. A., Taylor, I., & Wilhelm, S. M. (2006) · Methods in Enzymology · doi:10.1016/s0076-6879(05)07047-3 · Cited by 463
BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
Cantwell-Dorris, E. R., O'Leary, J. J., & Sheils, O. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0799 · Cited by 459
Molecular Classification and Correlates in Colorectal Cancer
Ogino, S., & Goel, A. (2008) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.070082 · Cited by 460
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer
Ciampi, R., Knauf, J. A., Kerler, R., Gandhi, M., Zhu, Z., Nikiforova, M. N., Rabes, H. M., Fagin, J. A., & Nikiforov, Y. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523237 · Cited by 461
“Indeed, activating point mutations of BRAF have been found in more than 60% of malignant melanomas, 10–14% of colorectal and ovarian cancer, and in very few cases of lung cancer, soft tissue sarcomas, and other cancer cell lines (14, 26, 27).”
BackgroundRaf proteins and cancer: B-Raf is identified as a mutational target
Mercer, K. E., & Pritchard, C. A. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00016-7 · Cited by 457
Imai, K., & Yamamoto, H. (2008) · Carcinogenesis · doi:10.1093/carcin/bgm228 · Cited by 429
B-RAF is a therapeutic target in melanoma
Karasarides, M., Chiloeches, A., Hayward, R., Niculescu-Duvaz, D., Scanlon, I., Friedlos, F., Ogilvie, L., Hedley, D., Martin, J., Marshall, C. J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207785 · Cited by 426
“…utility in other cancers where the B-RAF gene is mutated, such as 30% of lowgrade ovarian cancers (Singer et al., 2003), 35–70% of papillary thyroid cancers (Cohen et al., 2003; Kimura et al., 2003) and 10–15% of colorectal cancers (Davies et al., 2002; Rajagopalan et al., 2002; Yuen et al., 2002).”
BackgroundNew perspectives for targeting RAF kinase in human cancer
Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.79 · Cited by 404
Targeting the ERK signaling pathway in cancer therapy
Kohno, M., & Pouyssegur, J. (2006) · Annals of Medicine · doi:10.1080/07853890600551037 · Cited by 416
“In this respect, B-Raf has been reported to be mutated in 70% of malignant melanomas (15), in 33% of papillary thyroid carcinomas (41), and in lower frequencies in other cancers (42).”
BackgroundHigh prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu, X., Quiros, R. M., Gattuso, P., Ain, K. B., & Prinz, R. A. (2003) · PubMed · Cited by 415
Deng, G., Bell, I., Crawley, S., Gum, J., Terdiman, J. P., Allen, B. A., Truta, B., Sleisenger, M. H., & Kim, Y. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1118-3 · Cited by 409
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
Yokota, T., Ura, T., Shibata, N., Takahari, D., Shitara, K., Nomura, M., Kondo, C., Mizota, A., Utsunomiya, S., Muro, K., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.19 · Cited by 401
“None of the CRC patients in our study carried both KRAS and BRAF mutations, supporting the hypothesis that KRAS and BRAF mutations occur in a mutually exclusive manner (Rajagopalan et al, 2002; Frattini et al, 2004; Ahlquist et al, 2008).”
BackgroundResultOmholt, K., Platz, A., Kanter, L., Ringborg, U. K., & Hansson, J. (2003) · PubMed · Cited by 399
Raf Family Kinases: Old Dogs Have Learned New Tricks
Matallanas, D., Birtwistle, M., Romano, D., Zebisch, A., Rauch, J., von Kriegsheim, A., & Kolch, W. (2011) · Genes & Cancer · doi:10.1177/1947601911407323 · Cited by 386
“Interestingly, B-Raf mutations normally do not coexist with oncogenic mutations in Ras in human tumors, arguing that they are equivalent in their transforming effects.(315) This conclusion indeed highlights B-Raf as a critical effector of Ras in cell transformation and cancer.”
BackgroundContributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
Steelman, L. S., Abrams, S. L., Whelan, J., Bertrand, F. E., Ludwig, D. E., Bäsecke, J., Libra, M., Stivala, F., Milella, M., Tafuri, A., et al. (2008) · Leukemia · doi:10.1038/leu.2008.26 · Cited by 385
Autocrine PDGFR signaling promotes mammary cancer metastasis
Jechlinger, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24652 · Cited by 371
Heat shock protein 90: The cancer chaperone
Neckers, L. (2007) · Journal of Biosciences · doi:10.1007/s12038-007-0051-y · Cited by 365
“Since B-Raf is mutated in approximately 60% of melanomas and to a lesser degree in other cancers ( Rajagopalan et al 2002 ), and since cells expressing mutated B-Raf appear to be dependent on its activity for their survival, Hsp90 inhibitors may have wide applicability in melanoma.”
BackgroundBRAF mutations are associated with some histological types of papillary thyroid carcinoma
Trovisco, V., Vieira de Castro, I., Soares, P., Máximo, V., Silva, P., Magalhães, J., Abrosimov, A., Guiu, X. M., & Sobrinho‐Simões, M. (2004) · The Journal of Pathology · doi:10.1002/path.1511 · Cited by 363
“The BRAF mutation has already been described in a follicular adenoma of the thyroid [6] and in colorectal carcinoma and melanoma [7,11].”
BackgroundSessile Serrated Adenoma (SSA) vs. Traditional Serrated Adenoma (TSA)
Torlakovic, E. E., Gomez, J. D., Driman, D. K., Parfitt, J. R., Wang, C., Benerjee, T., & Snover, D. C. (2008) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318157f002 · Cited by 348
“As BRAF and Kras mutations are mutually exclusive, if this is true it further supports that SSA and TSA are indeed biologically different.(33) Our current results will simplify the morphologic distinction between the 2 lesions by providing more objective criteria for assessment, hopefully allowing this to be better ev…”
ResultMutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
Tannapfel, A., Sommerer, F., Benicke, M., Katalinic, A., Uhlmann, D., Witzigmann, H., Hauss, J., & Wittekind, C. (2003) · Gut · doi:10.1136/gut.52.5.706 · Cited by 343
Colorectal cancer molecular biology moves into clinical practice
Pritchard, C. C., & Grady, W. M. (2011) · Gut · doi:10.1136/gut.2009.206250 · Cited by 344
Defining ‘chromosomal instability’
Geigl, J. B., Obenauf, A. C., Schwarzbraun, T., & Speicher, M. R. (2008) · Trends in Genetics · doi:10.1016/j.tig.2007.11.006 · Cited by 341
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing
Domingo, E., Laiho, P., Ollikainen, M., Pinto, M., Wang, L., French, A. J., Westra, J., Frebourg, T., Espín, E., Armengol, M., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.020651 · Cited by 339
Awada, A., Hendlisz, A., Gil, T., Bartholomeus, S., Mano, M., de Valeriola, D., Strumberg, D., Brendel, E., Haase, C. G., Schwartz, B., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602584 · Cited by 339
“BAY 43-9006 also slowed tumour growth of ovarian cancer derived from the SKOV-3 cell line, which contains wild-type K-Ras but overexpresses epidermal growth factor and HER-2 receptors (Gianpaolo-Ostravage et al, 2001; Lyons et al, 2001).”
BackgroundBarault, L., Veyrie, N., Jooste, V., Lecorre, D., Chapusot, C., Ferraz, J., Lièvre, A., Cortet, M., Bouvier, A., Rat, P., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23388 · Cited by 331
Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes
Sinicrope, F. A., Shi, Q., Smyrk, T. C., Thibodeau, S. N., Dienstmann, R., Guinney, J., Bot, B. M., Tejpar, S., Delorenzi, M., Goldberg, R. M., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.09.041 · Cited by 330
“BRAF is a member of the Raf kinase family that is a regulator of the MAP kinase/ERK signaling pathway.(7,8) BRAF mutations occur downstream from and are mutually exclusive of KRAS codon 12 and 13 mutations(8) that are detected in 30%–40% of CRCs.”
Therapeutic Strategies for Targeting Ras Proteins
Gysin, S., Salt, M., Young, A., & McCormick, F. (2011) · Genes & Cancer · doi:10.1177/1947601911412376 · Cited by 323
BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas.
Chan, T. L., Zhao, W., Leung, S. Y., & Yuen, S. T. (2003) · PubMed · Cited by 319
Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines
Hollestelle, A., Elstrodt, F., Nagel, J. H. A., Kallemeijn, W. W., & Schutte, M. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0263 · Cited by 320
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Gavin, P. G., Colangelo, L. H., Fumagalli, D., Tanaka, N., Remillard, M. Y., Yothers, G., Kim, C., Taniyama, Y., Kim, S. I., Choi, H. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0605 · Cited by 320
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319
“In addition, BRAF mutations are limited to tumors that do not carry the RAS mutation [55].”
BackgroundAssociation of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab
Ince, W. L., Jubb, A. M., Holden, S. N., Holmgren, E. B., Tobin, P., Sridhar, M., Hurwitz, H. I., Kabbinavar, F., Novotny, W. F., Hillan, K. J., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji174 · Cited by 319
Colorectal serrated adenocarcinoma
Mäkinen, M. J. (2007) · Histopathology · doi:10.1111/j.1365-2559.2006.02548.x · Cited by 316
“The most common BRAF mutation (V600E, formerly V599E) results in a constitutively activated enzyme.(129) It has been identified in 5–15% of CRCs and is strongly associated with DNA methylation and MSI.”
BackgroundSouglakos, J., Philips, J., Wang, R., Marwah, S., Silver, M., Tzardi, M., Silver, J., Ogino, S., Hooshmand, S., Kwak, E., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605164 · Cited by 310
“As the two mutations tend to be mutually exclusive (Rajagopalan et al, 2002; Yuen et al, 2002), KRAS is inferred to signal principally through BRAF in colon cancer cells, leading to an assumption that tumours with KRAS or BRAF mutations may be equally vulnerable to inhibition of BRAF.”
BackgroundSinicrope, F. A., & Sargent, D. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1469 · Cited by 309
The genetics of malignant melanoma: lessons from mouse and man
Chin, L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1145 · Cited by 302
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?
Repasky, G. A., Chenette, E. J., & Der, C. J. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.09.014 · Cited by 300
Henson, E. S., & Gibson, S. B. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.05.015 · Cited by 300
Raf: A Strategic Target for Therapeutic Development Against Cancer
Beeram, M., Patnaik, A., & Rowinsky, E. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.036 · Cited by 298
Activating FGFR2–RAS–BRAF Mutations in Ameloblastoma
Brown, N. A., Rolland, D., McHugh, J. B., Weigelin, H. C., Zhao, L., Lim, M. S., Elenitoba-Johnson, K. S. J., & Betz, B. L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1069 · Cited by 298
“Thismutation is present innumerous neoplasms, including melanoma (12), hairy cell leukemia (13), papillary thyroid carcinoma (14), Langerhans cell histiocytosis (15), and colorectal cancer (16).”
Background
Metadata
- Authors
- Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E.
- Affiliations
- Johns Hopkins University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Velculescu, Victor E.
- Venue
- Nature
- Published
- 2002-08-29
- Volume
- 418
- Issue
- 6901
- Pages
- 934-934
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985035689
- Cited by
- 1,224
- References
- 8
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 29 · 2023: 30 · 2022: 26 · 2021: 42 · 2020: 38 · 2019: 35 · 2018: 41 · 2017: 42 · 2016: 51 · 2015: 76 · 2014: 65 · 2013: 74 · 2012: 78
- FWCI
- 37.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- BRAF mutation, KRAS mutation, oncogenic Ras, DNA mismatch repair, colorectal cancer, melanoma, carcinogenesis, DNA repair, mutation spectrum, growth factor signaling
- MeSH terms
- DNA Damage, DNA Repair, Gene Frequency, Humans, Mutation, Oncogenes, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins c-raf, Base Pair Mismatch
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.